BIOMAT Database Logo BIOMAT Database Logo

An analysis of prognostic factors in stage III and IV Hodgkin's disease treated at a single centre with MVPP. 1991

M R Ranson, and J A Radford, and R Swindell, and D P Deakin, and P M Wilkinson, and M Harris, and R J Johnson, and D Crowther
Department of Medical Oncology, CRC University of Manchester, UK.

Two hundred and twenty seven patients with stage IIIA-IVB Hodgkin's disease have been treated at a single centre with MVPP chemotherapy followed by radiotherapy to sites of previously bulk disease. The median follow up is 58 months. 119 patients (52%) had stage IV disease. Overall complete remission (CR) rate was 72%. Discriminant analysis of factors predictive for complete remission showed that low albumin was the only independent factor that predicted a significantly lower chance of CR. Overall five year survival was 73%. A Cox multivariate analysis demonstrated that age greater than 40 years, stage IV disease, presence of bulk disease, low serum IgG and male sex to be variables which independently predicted poorer prognosis in terms of overall survival. Stage IV and lymphocyte depleted or unclassified histologies were independently predictive for poorer progression-free survival. Patient weight greater than 70 kg and stage IV disease were adverse prognostic factors for relapse free survival. Results are compared to other published multivariate analyses of prognostic factors in advanced Hodgkin's disease.

UI MeSH Term Description Entries
D008297 Male Males
D008466 Mechlorethamine A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA. Chlorethazine,Chlormethine,Mechlorethamine Oxide,Mustine,Nitrogen Mustard,Nitrogen Mustard N-Oxide,Bis(2-chloroethyl)methylamine,Caryolysine,Cloramin,Embichin,Mechlorethamine Hydrochloride,Mechlorethamine Hydrochloride N-Oxide,Mechlorethamine N-Oxide,Methylchlorethamine,Mitomen,Mustargen,NSC-10107,NSC-762,Nitrogranulogen,Nitromin,Hydrochloride N-Oxide, Mechlorethamine,Hydrochloride, Mechlorethamine,Mechlorethamine Hydrochloride N Oxide,Mechlorethamine N Oxide,N-Oxide, Mechlorethamine Hydrochloride,N-Oxide, Nitrogen Mustard,NSC 10107,NSC 762,NSC10107,NSC762,Nitrogen Mustard N Oxide
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D011344 Procarbazine An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. Matulane,Natulan,Procarbazine Hydrochloride,Procarbazine Monohydrobromide,Procarbazine Monohydrochloride,Hydrochloride, Procarbazine,Monohydrobromide, Procarbazine,Monohydrochloride, Procarbazine
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

M R Ranson, and J A Radford, and R Swindell, and D P Deakin, and P M Wilkinson, and M Harris, and R J Johnson, and D Crowther
[Prognostic factors concerning the survival time of Hodgkin's disease stage III and IV, treated with cytostatic agents].
April 1976, Schweizerische medizinische Wochenschrift,
M R Ranson, and J A Radford, and R Swindell, and D P Deakin, and P M Wilkinson, and M Harris, and R J Johnson, and D Crowther
Prognostic factors in Hodgkin's disease stage IV.
October 1988, European journal of haematology,
M R Ranson, and J A Radford, and R Swindell, and D P Deakin, and P M Wilkinson, and M Harris, and R J Johnson, and D Crowther
Prognostic factors for Stage IV Hodgkin's disease treated with MOPP, with or without bleomycin.
February 1985, Cancer,
M R Ranson, and J A Radford, and R Swindell, and D P Deakin, and P M Wilkinson, and M Harris, and R J Johnson, and D Crowther
Prognostic factors in pathologic stage III Hodgkin's disease.
April 1982, Cancer treatment reports,
M R Ranson, and J A Radford, and R Swindell, and D P Deakin, and P M Wilkinson, and M Harris, and R J Johnson, and D Crowther
Factors affecting remission and survival in patients with advanced Hodgkin's disease treated with MVPP.
January 1986, Hematological oncology,
M R Ranson, and J A Radford, and R Swindell, and D P Deakin, and P M Wilkinson, and M Harris, and R J Johnson, and D Crowther
An analysis of prognostic factors in early stage Hodgkin's disease.
October 1986, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
M R Ranson, and J A Radford, and R Swindell, and D P Deakin, and P M Wilkinson, and M Harris, and R J Johnson, and D Crowther
Evaluation of the significance of prognostic factors in stage III Hodgkin's disease treated with MOPP and radiotherapy.
March 1980, Cancer,
M R Ranson, and J A Radford, and R Swindell, and D P Deakin, and P M Wilkinson, and M Harris, and R J Johnson, and D Crowther
[New prognostic factors in the treatment of patients with stage-III Hodgkin's disease].
January 2010, Voprosy onkologii,
M R Ranson, and J A Radford, and R Swindell, and D P Deakin, and P M Wilkinson, and M Harris, and R J Johnson, and D Crowther
Prognostic factors in Hodgkin's disease stage III with special reference to tumour burden.
July 1988, European journal of haematology,
M R Ranson, and J A Radford, and R Swindell, and D P Deakin, and P M Wilkinson, and M Harris, and R J Johnson, and D Crowther
A multivariate analysis of prognostic factors in early stage Hodgkin's disease.
January 1985, International journal of radiation oncology, biology, physics,
Copied contents to your clipboard!